Skip to content
lifestyle.healthsourcemag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ipsen Pharma
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
May 25, 2026
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
May 25, 2026
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
May 24, 2026
←
Previous Page
1
2